Ionis Pharmaceuticals (IONS) P/E ratio
The P/E ratio of Ionis Pharmaceuticals (IONS) was 31.8× at the end of fiscal 2019 (December 31, 2019). That is 21.7% higher than the 26.1× of fiscal 2018. Figures as of 18 Nov 2026, 06:19 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio, fiscal 2019
- 31.8×
- Change on fiscal 2018
- +21.7%
- Highest on record
- 335.3×fiscal 2017
- Lowest on record
- 7.0×fiscal 2009
- Fiscal years on record
- 42009–2019
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Ionis Pharmaceuticals P/E ratio, in more detail
Across the 4 fiscal year-ends on record (2009–2019), the highest was 335.3× in fiscal 2017 and the lowest 7.0× in fiscal 2009.
P/E ratio at each fiscal year-end
Ionis Pharmaceuticals P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | $79.11 | -$2.38 | |
| 2024 | — | — | $34.96 | -$3.04 | |
| 2023 | — | — | $50.59 | -$2.56 | |
| 2022 | — | — | $37.77 | -$1.90 | |
| 2021 | — | — | $30.43 | -$0.20 | |
| 2020 | — | — | $56.54 | -$3.18 | |
| 2019 | 31.8× | 21.7% up | $60.41 | $1.90 | |
| 2018 | 26.1× | 92.2% down | $54.06 | $2.07 | |
| 2017 | 335.3× | — | $50.30 | $0.15 | |
| 2016 | — | — | $47.83 | -$0.50 | |
| 2015 | — | — | $61.93 | -$0.74 | |
| 2014 | — | — | $61.74 | — | |
| 2013 | — | — | $39.84 | — | |
| 2012 | — | — | $10.44 | — | |
| 2011 | — | — | $7.21 | -$0.85 | |
| 2010 | — | — | $10.12 | -$0.62 | |
| 2009 | 7.0× | — | $11.11 | $1.58 | |
| 2008 | — | — | $14.18 | -$0.19 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Edgewise Therapeutics EWTX | 5.2× |
| LivaNova LIVN | 26.5× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
Ionis Pharmaceuticals, figure by figure
- Ionis Pharmaceuticals market cap
- Ionis Pharmaceuticals revenue
- Ionis Pharmaceuticals earnings
- Ionis Pharmaceuticals earnings per share (EPS)
- Ionis Pharmaceuticals P/S ratio
- Ionis Pharmaceuticals P/B ratio
- Ionis Pharmaceuticals free cash flow
- Ionis Pharmaceuticals operating margin
- Ionis Pharmaceuticals dividend
- Ionis Pharmaceuticals shares outstanding
- Ionis Pharmaceuticals total debt
- Ionis Pharmaceuticals cash on hand
- Ionis Pharmaceuticals total assets
- Ionis Pharmaceuticals return on equity (ROE)
- Ionis Pharmaceuticals return on invested capital (ROIC)
Ionis Pharmaceuticals (IONS) overview: price, valuation and scorecardAll health care companies by market value
Ionis Pharmaceuticals P/E ratio: questions and answers
What is Ionis Pharmaceuticals's P/E ratio?
The P/E ratio of Ionis Pharmaceuticals (IONS) was 31.8× at the end of fiscal 2019 (December 31, 2019). That is 21.7% higher than the 26.1× of fiscal 2018.
What are the highest and lowest P/E ratio figures on record for Ionis Pharmaceuticals?
Across the 4 fiscal year-ends on record (2009–2019), the highest was 335.3× in fiscal 2017 and the lowest 7.0× in fiscal 2009.
How is Ionis Pharmaceuticals's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Ionis Pharmaceuticals (IONS) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/IONS/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.